Medincell SA (MEDCL)

Currency in EUR
24.10
-0.40(-1.63%)
Closed·
MEDCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.0024.36
52 wk Range
16.6439.68
Key Statistics
Prev. Close
24.5
Open
24.32
Day's Range
23-24.36
52 wk Range
16.64-39.68
Volume
56.79K
Average Volume (3m)
94.63K
1-Year Change
41.6814%
Book Value / Share
0.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MEDCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.51
Upside
+43.20%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Medincell SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.51
(+43.20% Upside)

Earnings

Latest Release
Jun 16, 2026
EPS / Forecast
-0.45 / -0.15
Revenue / Forecast
10.13M / 6.4M
EPS Revisions
Last 90 days

MEDCL Income Statement

Compare MEDCL to Peers and Sector

Metrics to compare
MEDCL
Peers
Sector
Relationship
P/E Ratio
−27.7x18.5x−0.4x
PEG Ratio
0.540.020.00
Price/Book
282.5x2.5x2.6x
Price / LTM Sales
35.6x2.1x3.1x
Upside (Analyst Target)
41.1%42.1%47.8%
Fair Value Upside
Unlock5.3%6.2%Unlock

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.

Employees
141
Market
France

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.71M18.68%161.65M
Other Institutional Investors
4.23M11.79%102.05M
Public Companies & Retail Investors
24.97M69.53%601.77M
Total
35.91M100.00%865.47M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Mirova Société Anonyme5.98%2,146,36451,727
Groupe Industriel Marcel Dassault4.64%1,664,66040,118

People Also Watch

27.86
AL2SI
+0.36%
6.59
ALKAL
-3.80%
102.70
ABVX
-3.66%
130.90
VU
-1.80%
129.20
SOIT
-3.00%

FAQ

What Is the Medincell (MEDCL) Stock Price Today?

The Medincell stock price today is 24.10 EUR.

What Stock Exchange Does Medincell Trade On?

Medincell is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Medincell?

The stock symbol for Medincell is "MEDCL."

What Is the Medincell Market Cap?

As of today, Medincell market cap is 865.47M EUR.

What Is Medincell's Earnings Per Share (TTM)?

The Medincell EPS (TTM) is -0.94.

When Is the Next Medincell Earnings Date?

Medincell will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is MEDCL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Medincell Stock Split?

Medincell has split 0 times.

How Many Employees Does Medincell Have?

Medincell has 141 employees.

What is the current trading status of Medincell (MEDCL)?

As of Aug 15, 2026, Medincell (MEDCL) is trading at a price of 24.10 EUR, with a previous close of 24.50 EUR. The stock has fluctuated within a day range of 23.00 EUR to 24.36 EUR, while its 52-week range spans from 16.64 EUR to 39.68 EUR.

What Is Medincell (MEDCL) Price Target According to Analysts?

The average 12-month price target for Medincell is 34.51 EUR, with a high estimate of 39 EUR and a low estimate of 30 EUR. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.20% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.